BullQuake- CWRN 360 % EXOU 290 % TEMN 214 %
Big Board Plays
APOL (Apollo Group Inc.)- APOL was alerted at 34.50 mid week, shortly after APOL surged hitting over $40 per share.
Monster Penny Picks
CWRN (Cotton & Western Mining, Inc.) CWRN was our Play for the week! This company was alerted to our members at only 0.006, then within just a blink of an eye she Sky Rocketed over 0.02 per share! That’s Possible Gains for You of Over 360 % in just a few short days!
EXOU (Exousia Advanced Materials, Inc) EXOU Exploded up Over 290 % from our Friday Morning Alert.
TEMN (Team Nations Holdings Group) printed 0.0022 early this week after our initial alert at 0.0007! Giving Gains of 214 % plus!
BOPH (Bohai Pharmaceuticals Group, Inc.) BOPH continues its ascent from the high dollar range finishing up the week at over $2.20 per share.
Please remember to do your due diligence. To view our full disclaimer please click here
What an EXPLOSIVE week for our portfolio!
What an EXPLOSIVE week for our portfolio! Several stocks alerted on our watch list made Massive Profits!
Big Board Plays
BBY (Best Buy Co. Inc) - We alerted our members intraday of a possible bounce play around 35.15, shortly after BBY surged over $36 per share!
Monster Penny Picks
CPOW (Clean Power Concepts) – Ran up over 80% on Friday from our alert Wednesday Morning!!
FRXP (Greenworld Dev) – Was our penny loser for the week with possible gains of only 10%.. But hey profit is profit!!
IDEH (Intl Dev & Enviro Hldg) – After alerting our members Monday morning IDEH pushed hard, giving our members the opportunity to lock in 50% gains or Higher!!
For the Absolute best stock alerts and leading edge in today’s market stay tuned intraday to our twitter at @BullQuake.com
Don’t have a twitter account? Sign up today at www.twitter.com
Never Miss Another Alert, Get Twitter on your Mobile Phone Today 100% Free!
For Android – http://download.cnet.com/Twitter-for-Android-official/3000-2150_4-11379115.html
For BlackBerry- http://appworld.blackberry.com/webstore/content/8160
For iPhone – http://download.cnet.com/Twitter/3000-12941_4-75108095.html?tag=mncol;2
Please remember to do your due diligence. To view our full disclaimer please click here
Bullquake is Back in Action! More Exclusive Offers & Extremely Profitable Stock Alerts Headed Your Way!
Hello Everyone!
Bullquake is Back in Action! We are constantly searching the market for the next Major Mover so you don’t have too!
Each day we will alert you to the top premarket watch lists via twitter, the next move is up too you.
We release the biggest movers each and every week. As a bonus our subscribers will have access to weekly recaps and exclusive offers.
See why thousands of investors come to Bullquake for the leading edge! Don’t miss out on another alert! http://twitter.com/bullquake/
This Past Week’s Biggest Gainers -
CELG- Alerted at $54.50, ran to over $57.50
HBRM- Alerted at $0.005 ran to over $0.008 with more than 6 Million in Volume
YOKU- Alerted on IPO in the mid 20’s, two days later YOKU reached a high of $50 per share
MCP- Alerted as a possible Short Sell above $33, members had the opportunity to cover below $31
Now ask yourself, are you ready to profit?
Please remember to do your due diligence. To view our full disclaimer please click here
HIDE at First Glimpse- An Early Penny Pick Alert
HIDE at First Glimpse
Early Penny Pick Alert (Pk)
HIDE was brought to our attention from the increasing activity that we noticed over the past few weeks. After doing our DD and looking over the chart we feel positive that HIDE could make a major move to the upside very soon. We highly suggest that everyone do their research on this hidden gem and keep a very close eye on it in the mean time.
With over 100 years of combined telecom experience, Nucentcom Inc has established undisputable trust and long lasting relationships with numerous corporations across the globe. To meet the demands of a constantly changing global market, Nucentcom Inc’s world class customer service representatives are multilingual and operate 24/7.
About HIDE (Nucentcom Inc)
Nucentcom, Inc. is a state-of-the-art, facilities-based telecommunications and technology company specializing in providing retail, wholesale (carrier’s carrier) and other telecommunications services to carriers and subscribers in North America, Europe and Asia through the innovative use of proven technologies. Our proprietary call-processing methodology and innovative technology enable the deployment of a variety of revenue-generating services. To date the company has focused on three areas of telecommunications:
Retail Telecommunication Services – In addition to Broadband dial tone and dial around retail products, Nucentcom is creating a private VoIP network for its UPASS-Enabled Homepage with E-Commerce subscribers, whereby individuals in different countries will be able to make high quality calls to each other, for one low, monthly fixed cost.
Wholesale Carrier Solutions – Nucentcom offers wholesale services through our worldwide network to carriers, telephony resellers and others around the world by operating through various Interconnection Agreements with Telecommunication Authorities in India, Pakistan, the Middle East and Latin America.
Municipal NuMAX Networks – Nucentcom has developed a system to work with municipalities to construct a wireless network that would allow broadband internet access and other ancillary services throughout the municipality.
Nucentcom Inc Leading Platforms Support the Following Applications:
• Prepaid and Post Paid Long Distance Calling Services including traditional card-based, ANY-authenticated, and real-time rated “Bucket-of-Minutes” implementations for integration with your existing Class 5 Broadband Telephony Services
• Highly Scalable Reservation-less Audio Conferencing Services
• Voice Mail and Unified Messaging
• Full featured Class 5 Residential and Business Broadband Telephony
• Web based applications and services
Our platform provides the carrier-grade scalability and high availability needed for network-hosted Services connected to SIP or H323 enabled PSTN-to-IP Media Gateways or Session Border Controllers. This full featured SDP environment – Solaris/Linux based – includes a standards-based Application Server, Media Server, and a graphically customizable portal.
Link to HIDE’s Chart
Please remember to do your due diligence. To view our full disclaimer please click here
BullQuake- ZIPZ, LVCA, & AEZS Afternoon Recap
We first alerted ZIPZ to our members at 0.0005 yesterday afternoon. Since our alert ZIPZ has Bullishly Roared up Over 100%, testing 0.0013 for the HOD.
LVCA- We alerted this one premarket, during mid afternoon LVCA had already made our members over 12%.
AEZS- We alerted our members on Twitter mid at 1.57 about the potential for a rebound, since then AEZS has climbed to a high of 1.77! We firmly believe AEZS could start a bullish uptrend headed into the ASCO, which is scheduled for early June.
Please remember to do your due diligence. To view our full disclaimer please click here
Breaking News: (AEZS) Aeterna Zentaris: Data on Lead Anticancer Compounds Perifosine and AEZS-108 to be Presented at Upcoming ASCO Annual Meeting
QUÉBEC CITY, May 21 /PRNewswire-FirstCall/ – Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the “Company”) a late-stage drug development company specialized in oncology and endocrine therapy, today announced that data on two of its lead anticancer compounds, perifosine and AEZS-108, will be presented at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4 through 8, 2010 at McCormick Place in Chicago. Two posters on perifosine, Aeterna Zentaris’ novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, will be presented in pediatric solid tumors and colorectal cancer. A poster will also be presented on the Company’s doxorubicin targeted conjugate compound, AEZS-108, in ovarian cancer.
Abstracts selected for presentation are as follows:
Perifosine
----------
Abstract # 9540: "Phase I Study of Single Agent Perifosine for
Recurrent Pediatric Solid Tumors"
Lead Author: Oren J. Becher, MD, Memorial Sloan-Kettering Cancer
Center
Presenter: Mark Kieran, MD, PhD, Dana-Farber Cancer Institute
Date and Time: Sunday, June 6, 2010, 2 pm-6 pm (poster discussion
5:40pm-6pm)
Poster Board #: 42b
Location: S Hall A2 (poster discussion in S504)
Abstract # 3531: "Final results of a randomized Phase II study of
perifosine in combination with capecitabine (P-CAP)
vs. placebo plus capecitabine (CAP) in patients (pts)
with second or third line metastatic colorectal
cancer (mCRC)"
Lead Author: Donald A. Richards, MD, PhD, Texas Oncology
Presenter: Wells Messersmith, MD, University of Colorado
Date and Time: Tuesday, June 8, 2010, 8 am-12 noon (poster
discussion 11:45 am-12 noon)
Poster Board #: 22
Location: S403 (poster discussion in S406)
AEZS-108
--------
Abstract # 5035: "Phase 2 study of AEZS-108, a targeted cytotoxic LHRH
analog, in patients with LHRH receptor positive
platinum resistant ovarian cancer"
Lead Author: Prof. Günter Emons, Chairman, Department of
Obstetrics & Gynaecology Georg-August University
Gottingen, Germany
Presenter: Prof. Günter Emons
Date and Time: Saturday, June 5, 2010 2pm- 6pm
Poster Board #: 45B
Location: S Hall A2
Copies of these abstracts are currently available and can be viewed on-line through the ASCO website: www.asco.org.
About Perifosine
Perifosine, a novel, potentially first-in-class, oral Akt inhibitor, is currently in Phase 3 trials for multiple myeloma and advanced colorectal cancer, under Special Protocol Assessment and Fast Track designation granted by the Food and Drug Administration (FDA) for both indications. FDA has also granted perifosine orphan-drug status for multiple myeloma. Furthermore, the European Medicines Agency (EMA) has issued a positive Scientific Advice as well as a positive opinion for Orphan Medicinal Product designation for perifosine for multiple myeloma.
Perifosine is also in a Phase 1 trial in pediatric patients, as well as in other Phase 1 and Phase 2 trials for several other tumor types.
Keryx Biopharmaceuticals, Inc. (Keryx) (Nasdaq:KERX – News) is Aeterna Zentaris’ partner and licensee for perifosine in the United States, Canada and Mexico. Perifosine is also out-licensed to Handok for South Korea, while Aeterna Zentaris retains rights for the rest of the world.
About AEZS-108
AEZS-108, a doxorubicin LHRH receptor targeted conjugate, is currently in a Phase 2 trial in advanced ovarian and endometrial cancer for which final results are expected before year-end. AEZS-108 has been granted orphan-drug designation by the FDA and has received a positive opinion for Orphan Medicinal Product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of ovarian cancer. An IND in the U.S. is in place for the treatment of bladder cancer.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.
http://finance.yahoo.com/news/Aeterna-Zentaris-Data-on-Lead-prnews-473193775.html?x=0&.v=3
Please remember to do your due diligence. To view our full disclaimer please click here
Cytori Therapeutics (NASDAQ: CYTX) Reports Stem & Regenerative Cells from Body Fat Improve Outcomes in Heart Attack Clinical Trial; Plans Underway for European Multicenter Pivotal Trial
Cytori Therapeutics (NASDAQ: CYTX) Reports Stem & Regenerative Cells from Body Fat Improve Outcomes in Heart Attack Clinical Trial; Plans Underway for European Multicenter Pivotal Trial
The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump. Based on positive safety and feasibility outcomes, and the biological, physiological and functional effects from this pilot study, plans are underway by Cytori Therapeutics (NASDAQ: CYTX), the trial sponsor, to initiate a European medical device approval study for the Celution® System, the cell processing system used in the study. More detailed information on this study and the results from a separate study in chronic heart disease patients may be found at the following link: cytoritx.presslift.com/cardiacdata.
Six-month results from the 14 patient, double-blind, placebo controlled study, referred to as the APOLLO trial, were reported today by Henrickus J. Duckers, M.D., Ph.D., Interventional Cardiologist, Head of Molecular Cardiology, Thoraxcentre, Erasmus University Hospital and co-Principal Investigator for the trial, at the 7th International Symposium on Stem Cell Therapy & Cardiovascular Innovation in Madrid, Spain. Highlights of the study’s six month outcomes are as follows:
The Celution® System-based procedure could be safely performed in an acute setting with no side effects from cell delivery, and no increase in arrhythmias
The study showed a 13.3% absolute reduction in the left ventricular infarct size (the portion of the heart not receiving blood to support pumping) in the treated group versus 8.2% in the placebo group from baseline to six months, based on blinded assessment of MRI data by an independent core laboratory. These data represent matched-pair analysis and exclude two patients whose follow up MRIs were not available. For the entire cohort of patients, mean infarct size improved from 31.6% at baseline to 15.4% at 6 months in cell-treated patients, and remained unchanged at 24.7% in the placebo group. The relevance of this reduction is that based on published literature, patients with an infarct size below 18% have a significantly lower risk of major adverse cardiac events (MACE) than those who are above this level
There was a 3.5 fold greater improvement in perfusion within the left ventricle in the cell treated group (6.0) compared to the placebo group (1.7), as measured by SPECT Visual Rest Scores (nuclear imaging of the heart)
Ejection fraction was measured by four imaging modalities. The greatest absolute change was found in the SPECT (single photon emission computed tomography) analysis, which showed a 5.7% absolute improvement in the cell treated group (+4.0%) compared to placebo (-1.7%)
“Improvements in infarct size, perfusion and ejection fraction are reflective of improvement in the overall cardiovascular health of a patient,” said Dr. Duckers. “Infarct size in particular, based on emerging consensus by the medical community and literature, is what we believe to be the most important predictor of re-hospitalization for heart failure, subsequent infarct, and death. The outcomes from this study are very exciting and warrant moving into a pivotal trial for European approval.”
“The clinical data from APOLLO is consistent with Cytori’s comprehensive preclinical data, reinforcing that improved blood flow and reduction of infarct size are how these cells are believed to impart benefit,” said Marc H. Hedrick, M.D., president of Cytori. “Compared to other cell sources, adipose tissue, using the Celution® System, is the only approach whereby a patient can access a meaningful number of their own cells at the point-of-care. This is especially critical for heart attack patients, where successful outcomes are dependent on immediate coronary intervention.”
As part of the novel procedure, a small amount of fat tissue was removed from each patient’s abdomen shortly after his or her heart attack. Using a proprietary medical device, the Celution® System, developed by Cytori, stem and regenerative cells were quickly separated from each patient’s fat tissue and concentrated at the point-of-care in the catheter laboratory. The cells were then immediately injected into the patient’s coronary artery. Liposuction, processing, and cell delivery all took place within the same procedure.
The APOLLO study is led by co-Principal Investigators Patrick W. Serruys, MD, PhD, Professor of Interventional Cardiology at the Thoraxcentre, Erasmus University Hospital and Henrickus J. Duckers, M.D., Ph.D., Interventional Cardiologist, Head of Molecular Cardiology, Thoraxcentre, Erasmus University Hospital. Hospital General Universitario Gregorio Marañón in Madrid, led by Francisco F. Avilés M.D., PhD, Professor of Medicine and Chief of Department of Cardiology, also participated in this study.
“We would like to thank the patients, the investigators, and all who collaborated with us on this trial,” added Alex Milstein, M.D., Vice President of Clinical Development at Cytori. “We are working closely with our Notified Body in Europe to finalize the design and protocol for a pivotal heart attack study, which we expect to initiate in late 2010 to early 2011. This will be a European approval study that is expected to range in size from 150 to 250 patients.”
Please remember to do your due diligence. To view our full disclaimer please click here
Q1/10 Results Out Preformed Expectations, Cytori Therapeutics (CYTX)
Q1/10 total revenue was $4.4 M. The net loss for Q1/10 was $2.447 M or ($0.06) per share, which surpassed all expectations from leading analysts who estimated a 0.16 per share loss.
Q1/10 product revenues were $2.3 M from Celution® and StemSource® sales in Europe, Asia and the US (representing 19% product revenue growth over Q1/09 of $1.9 M and 80% growth over Q4/09) and $2.1 M in development revenue . The cumulative number of revenue generating systems grew to 110 in Q1/10 (compared to 59 in Q1/09). In addition, 342 consumables, including 261 re-orders were shipped (compared to 241 total consumables in Q1/09) and 164 being reorders.
Gross margin grew 59% (a gross profit of $1.3 M) in Q1/10 (compared with 43% in Q1/09). The improvement in margin is due largely to a greater proportion of direct sales and improved manufacturing efficiencies.
Total operating expenses were $5.6 M (compared to $6.4 M in Q1/09). Included in operating expenses was a $1.9 M net reduction in non-cash change in fair value of the warrant and option liability compared to a $0.8 M net reduction in Q1/09.
CYTX ended Q1/10 with $22.7 M in cash and cash equivalents (versus $12.9 M at 12/31/09) plus $2.7 M in accounts (net) recieveables. Subsequent to the end of Q1/10, CYTX raised an additional $2.3 M from the sale of stock through the equity agreement with Seaside 88, LP.
Q1/10 Highlights:
- Revenues grew from a mix of Celution® and StemSource® sales in Europe, Asia and the US,
- Growth of consumable reorders reflects the established and increasing base of customers integrating Celution® into their practices,
- CYTX also achieved their 2nd StemSource® Cell Bank installation in Japan; by an existing Celution® customer to meet growing patient demand,
- On 5/7/10, CYTX investigators will report results from 2 cardiac clinical trials: APOLLO for acute myocardial infarction (heart attack) and PRECISE for chronic myocardial ischemia, a severe form of chronic heart disease. Specifically, these results will be presented at the 7th International Symposium on Stem Cell Therapy and Cardiovascular Innovations in Madrid, Spain,
- More than 2,300 cumulative consumables have been shipped since commercialization began in Q1/08,
- A Pre-IDE meeting with the FDA is scheduled in May of 2010 to define clinical objectives needed for Celution® approval for soft tissue reconstruction.
About Cytori
CYTX- A Stock Pick That Mustn’T Miss!!
CYTX- Put this one on your watch list, Cytori Therapeutics will announce the results of their Chronic Heart Ischemia trials on May 6 & 7th. We feel CYTX could be trading very bullishly up until then, if the results are positive the stocks pps could go orbital! Be ready!!
About Cytori
For the Hottest intraday and premarket stock alerts keep a close eye on a twitter page. “Click the Icon Bellow.”
Please remember to do your due diligence. To view our full disclaimer please click here
Do we have your Attention Now? Our Members Continue to Make Huge Profits!
ABK- We alerted our members at 0.65 then it ran to 1.19! Over a 90% Return!
GETA- We alerted our members at 0.06 a week later she ran to a Monstrous high of 0.20! That’s Over 210%!
EXPU- We alerted our members at 0.055 shortly after this beauty was trading in the low 0.20′s!!
FRHV- We alerted our members at 0.002 then it ran to over 0.15 per share!!
BBI- We alerted our members at 0.289 then this stock soared to 0.60 per share a week later!!
Do we have your attention now? Do not miss our Leading Newsletter, The next Pick could be Huge!! “Click the Link Bellow.”
Do you have a friend thats interested in Trading? Have them sign up for Free Today!
For the Hottest intraday and premarket stock alerts keep a close eye on a twitter page. “Click the Icon Bellow.”
Please remember to do your due diligence. To view our full disclaimer please click here
